Press Releases

Lysogene, a gene therapy platform Company targeting central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its LYS-GM101 program, which is being studied in the recently initiated global adaptative-design clinical trial for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a fatal autosomal recessive disease caused by mutations in the GLB1 gene leading to accumulation of GM1 ganglioside in neurons r

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Laekna Therapeutics Shanghai Co., Ltd. (Laekna), an emerging innovative pharma company based in China's "Zhangjiang Pharma Valley" and New Jersey in the U.S., focusing on developing new ground-breaking innovative therapies to treat cancer and liver diseases, today j

Breckenridge Pharmaceutical, Inc. announces today that it has signed a multi-product agreement with Welding GmbH & Co. under which Welding will develop, manufacture and supply pharmaceutical products for marketing, sale and distribution by Breckenridge.  The agreement currently covers one delayed release tablet product and two injectable products.  Of these three products, one ANDA has been submitted to the U.S. Food and Drug Administration, one ANDA is expected to be submitted

VBI Vaccines Inc., a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Panel has established a unique CPT code for a 3-antigen (S, Pre-S1, Pre-S2) Hepatitis B (HBV) vaccine. If approved, VBI’s 3-antigen HBV vaccine candidate will be reported using the new code, differentiating it from other single-antigen HBV vaccines.

Philip Morris International Inc. announced today it has entered into an agreement to acquire Fertin Pharma A/S (Fertin Pharma), a leading developer and manufacturer of innovative pharmaceutical and well-being products based on oral and intra-oral delivery systems, for an enterprise value of DKK 5.1 billion (approximately USD 820 million1). “The acquisition of Fertin Pharma will be a significant step forward on our journey toward delivering a smoke-free future—enhancing o

Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Eisai received approval for DAYVIGO in Hong Kong on February 28, 2021, and this launch is the first for DAYVIGO in Asia outside of Japan. DAYVIGO is a dual orexin rece

Connecting the whole pharmaceutical value chain and focusing on manufacturing and packaging sides of the industry were the main directions of the Pharmaceutical Manufacturing and Packaging Congress 2021 (PHARMAP 2021). It took place on the BGS online platform on June 28-29, 2021, and raised the questions of the further industry development, continuous manufacturing, and intelligent packaging. The most cutting-edge pharmaceutical topics demand attention of the decision-makers from th

QIAGEN N.V. and Verogen Inc. today announced a partnership to provide laboratories with superior tools and comprehensive support for implementing next-generation sequencing (NGS) human identification workflows. The partnership with QIAGEN is a milestone-driven distribution and development agreement that grants QIAGEN rights to globally distribute both current and future Verogen products. Verogen and QIAGEN will also collaborate to commercialize Verogen’s forensically validated

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the government of India has issued a registration certificate and a permission to import the COVID-19 Vaccine Moderna for restricted use in an emergency situation. “I want to thank the government of India for this authorization, which marks an important step forward in the global fight against the pandemic,” said Stéphane Bancel, Chief Executive O

Frontage Holdings Corporation, today announced that its wholly-owned subsidiary, Frontage Laboratories, Inc., has entered into a definitive agreement for the acquisition of Quintara Discovery, Inc. According to Dr. Song Li, founder, chairman and CEO of Frontage: "Quintara has an exceptional discovery and development platform that it has leveraged to build a strong reputation with its clients. Following the addition of the Quintara team's significant expertise in the areas o